Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 9

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Mar 7, 2017; 23(9): 1618-1626
Published online Mar 7, 2017. doi: 10.3748/wjg.v23.i9.1618

Table 4 Drug classes of medications identified as drug-drug interactions from baseline medication list n (%)

Drug class	Affected portion of the cohort n = 664
PPI/H₂RA agents	117 (17.6)
Antacids	72 (10.8)
Vitamin and herbal supplements	284 (42.7)
Hypertensive agents	53 (8.0)
Analgesics	67 (10.1)
Psychiatric agents	46 (6.9)
Anticonvulsants	4 (0.6)
Steroids	12 (1.8)
Others	126 (19.0)

PPI: Proton pump inhibitor; H₂RA: H₂-receptor antagonists.

Citation: Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World J Gastroenterol 2017; 23(9): 1618-1626
URL: https://www.wjgnet.com/1007-9327/full/v23/i9/1618.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i9.1618

Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World J Gastroenterol 2017; 23(9): 1618-1626 [PMID: 28321163 DOI: 10.3748/wjg.v23.i9.1618]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.